13D·WATCH Activist + Insider Intelligence Live feed Blog About Pilot
SCHEDULE Filed 2025-11-07 Event 2025-11-05 SEC 0001193125-25-272748 →

BCLS II Investco, LP NewAmsterdam Pharma Co N.V. NAMSW

Stake: 9.99% Shares: 11,422,504 CUSIP: N62509109 Class: Ordinary Shares, nominal value Euro 0.12 per share

Item 4 — Purpose of Transaction

Item 4 of the Initial Statement is hereby amended and supplemented to add the following: Nicholas Downing resigned from the Issuer's Board of Directors and its committees, effective as of November 5, 2025.

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
4 13D/G filings on this issuer
3 other filings besides this one
Filer Track Record
2 filings by this filer
1 other filing in the data moat
Short Interest · settle 2026-03-31
DTC 1.00
41 shares short · 0.0% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
1 holder · $108K
Duquesne Family Office

Other 13D/G Filings on NewAmsterdam Pharma Co N.V.

FiledFormFilerStakeShares
2025-09-30 SCHEDULE Forbion Capital Fund IV Cooperatief U.A. 8.30% 9,316,914 view →
2023-07-07 SC Forbion Capital Fund IV Cooperatief U.A. view →
2023-06-13 SC BCLS II Investco, LP view →

Other Filings by BCLS II Investco, LP

FiledFormIssuerStakeShares
2023-06-13 SC NewAmsterdam Pharma Co N.V. NAMSW view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →